Biological determinants of health disparities in prostate cancer

Current Opinion in Oncology

Volumn 25, Issue 3, 2013, Pages 235-241

  Martin, Damali N ^a   Starks, Adrienne M ^a   Ambs, Stefan ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

genetics; health disparity; outcome; prostate cancer; tumor marker

Indexed keywords

GLUTATHIONE TRANSFERASE P1; HERMES ANTIGEN;

AFRICAN AMERICAN; CANCER DIAGNOSIS; CANCER PATIENT; CELL PROLIFERATION; CHINESE; CHROMOSOME ABERRATION; CHROMOSOME REARRANGEMENT; DNA METHYLATION; ERYTHROBLAST; ETHNICITY; EUROPEAN AMERICAN; GENE DOSAGE; GENE EXPRESSION; GENE FUSION; GENE LOCUS; GENE MUTATION; HUMAN; IMMUNOBIOLOGY; INFLAMMATION; JAPANESE; MALE; MYELOID DENDRITIC CELL; ONCOGENE; PREVALENCE; PRIORITY JOURNAL; PROSTATE CANCER; RACE; RACE DIFFERENCE; REVIEW; TREATMENT RESPONSE;

AFRICAN CONTINENTAL ANCESTRY GROUP; DNA METHYLATION; GENOME-WIDE ASSOCIATION STUDY; HEALTH STATUS DISPARITIES; HUMANS; MALE; ONCOGENES; PROSTATIC NEOPLASMS;

EID: 84876295525     PISSN: 10408746     EISSN: 1531703X     Source Type: Journal    
DOI: 10.1097/CCO.0b013e32835eb5d1     Document Type: Review

References (45)

1. Zeigler-Johnson CM, Rennert H, Mittal RD, et al. Evaluation of prostate cancer characteristicsinfour populations worldwide. Can J Urol 2008; 15:4056-4064.
2. Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 2006; 24:2137-2150.
3. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011; 61:69-90.
4. Jemal A, Siegel R, Ward E, et al. Cancer statistics. CA Cancer J Clin 2009; 59:225-249.
5. Wallace TA, Martin DN, Ambs S. Interactions among genes, tumor biology and the environment in cancer health disparities: examining the evidence on a national and global scale. Carcinogenesis 2011; 32:1107-1121.
6. Powell IJ. Epidemiology and pathophysiology of prostate cancer in African-American men. J Urol 2007; 177:444-449.
7. Powell IJ, Bock CH, Ruterbusch JJ, Sakr W. Evidence supports a faster growth rate and/or earlier transformation to clinically significant prostate cancer in black than in white American men, and influences racial progression and mortality disparity. J Urol 2010; 183:1792-1796.
8. Eastham JA, May RA, Whatley T, et al. Clinical characteristics and biopsy specimen features in African-American and white men without prostate cancer. J Natl Cancer Inst 1998; 90:756-760.
9. Freedland SJ, Sutter ME, Naitoh J, et al. Clinical characteristics in black and white men with prostate cancer in an equal access medical center. Urology 2000; 55:387-390.
10. Mavropoulos JC, Partin AW, Amling CL, et al. Do racial differences in prostate size explain higher serum prostate-specific antigen concentrations among black men? Urology 2007; 69:1138-1142.
11. Freedman ML, Haiman CA, Patterson N, et al. Admixture mapping identifies 8q24 as aprostate cancer risk locus in African-American men. Proc Natl Acad Sci USA 2006; 103:14068-14073.
12. Amundadottir LT, Sulem P, Gudmundsson J, et al. A common variant associated with prostate cancer in European and African populations. Nat Genet 2006; 38:652-658.
13. Haiman CA, Patterson N, Freedman ML, et al. Multiple regions within 8q24 independently affect risk for prostate cancer. Nat Genet 2007; 39:638-644.
14. Haiman CA, Chen GK, Blot WJ, et al. Characterizing genetic risk at known prostate cancer susceptibility loci in African Americans. PLoS Genet 2011; 7:e1001387.
15. Woodson K, Hayes R, Wideroff L, et al. Hypermethylation of GSTP1, CD44, and E-cadherin genes in prostate cancer among US Blacks and Whites. Prostate 2003; 55:199-205.
16. Enokida H, Shiina H, Urakami S, et al. Ethnic group-related differences in CpG hypermethylation of the GSTP1 genepromoteramongAfrican-American, Caucasian and Asian patients with prostate cancer. Int J Cancer 2005; 116:174-181.
17. Kwabi-Addo B, Wang S, Chung W, et al. Identification of differentially methylated genes in normal prostate tissues from African American and Caucasian men. Clin Cancer Res 2010; 16:3539-3547.
18. - 18. Rose AE, Satagopan JM, Oddoux C, et al. Copy number and gene expression differences between African American and Caucasian American prostate cancer. J Transl Med 2010; 8:70.
19. Mao X, Yu Y, Boyd LK, et al. Distinct genomic alterations in prostate cancers in Chinese and Western populations suggest alternative pathways of prostate carcinogenesis. Cancer Res 2010; 70:5207-5212.
20. Magi-Galluzzi C, Tsusuki T, Elson P, et al. TMPRSS2-ERG gene fusion prevalence and class are significantly different in prostate cancer of Caucasian, African-American and Japanese patients. Prostate 2011; 71:489-497.
21. Rosen P, Pfister D, Young D, et al. Differences in frequency of ERG oncoprotein expression between index tumors of Caucasian and African American patients with prostate cancer. Urology 2012; 80:749-753.
22. Wallace TA, Prueitt RL, Yi M, et al. Tumor immunobiological differences in prostate cancer between African-American and European-American men. Cancer Res 2008; 68:927-936.
23. Reams RR, Agrawal D, Davis MB, et al. Microarray comparison of prostate tumor gene expression in African-American and Caucasian American males: a pilot project study. Infect Agent Cancer 2009; 4 (Suppl 1):S3.
24. Nelson WG, De Marzo AM, Yegnasubramanian S. Epigenetic alterations in human prostate cancers. Endocrinology 2009; 150:3991-4002.
25. Jones J, Wang H, Zhou J, et al. Nuclear kaiso indicates aggressive prostate cancers and promotes migration and invasiveness of prostate cancer cells. Am J Pathol 2012; 181:1836-1846.
26. Adkins RM, Krushkal J, Tylavsky FA, Thomas F. Racial differences in gene-specific DNA methylation levels are present at birth. Birth Defects Res A Clin Mol Teratol 2011; 91:728-736.
27. Cher ML, Lewis PE, Banerjee M, et al. A similar pattern of chromosomal alterations in prostate cancers from African-Americans and Caucasian Americans. Clin Cancer Res 1998; 4:1273-1278.
28. Castro P, Creighton CJ, Ozen M, et al. Genomic profiling of prostate cancers from African American men. Neoplasia 2009; 11:305-312.
29. Tomlins SA, Laxman B, Dhanasekaran SM, et al. Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusionsin prostate cancer. Nature 2007; 448:595-599.
30. Kumar-Sinha C, Tomlins SA, Chinnaiyan AM. Recurrent gene fusions in prostate cancer. Nat Rev Cancer 2008; 8:497-511.
31. Rosen P, Sesterhenn IA, Brassell SA, et al. Clinical potential of the ERG oncoprotein in prostate cancer. Nat Rev Urol 2012; 9:131-137.
32. Setlur SR, Mertz KD, Hoshida Y, et al. Estrogen-dependent signaling in a molecularly distinct subclass of aggressive prostate cancer. J Natl Cancer Inst 2008; 100:815-825.
33. Miyagi Y, Sasaki T, Fujinami K, et al. ETS family-associated gene fusions in Japanese prostate cancer: analysis of 194 radical prostatectomy samples. Mod Pathol 2010; 23:1492-1498.
34. Dong JT, Li CL, Sipe TW, Frierson HF Jr. Mutations of PTEN/MMAC1 in primary prostate cancers from Chinese patients. Clin Cancer Res 2001; 7:304-308.
35. Orikasa K, Fukushige S, Hoshi S, et al. Infrequent genetic alterations of the PTEN gene in Japanese patients with sporadic prostate cancer. J Hum Genet 1998; 43:228-230.
36. Tomlins SA, Aubin SM, Siddiqui J, et al. Urine TMPRSS2:ERG fusion transcript stratifies prostate cancer risk in men with elevated serum PSA. Sci Transl Med 2011; 3:94ra72.
37. Srikantan V, Zou Z, Petrovics G, et al. PCGEM1, a prostate-specific gene, is overexpressed in prostate cancer. Proc Natl Acad Sci USA 2000; 97:12216-12221.
38. Petrovics G, Zhang W, Makarem M, et al. Elevated expression of PCGEM1, a prostate-specific gene with cell growth-promoting function, is associated with high-risk prostate cancer patients. Oncogene 2004; 23:605-611.
39. Timofeeva OA, Zhang X, Ressom HW, et al. Enhanced expression of SOS1 is detected in prostate cancer epithelial cells from African-American men. Int J Oncol 2009; 35:751-760.
40. Tsai YC, Mendoza A, Mariano JM, et al. The ubiquitin ligase gp78 promotes sarcoma metastasis by targeting KAI1 for degradation. Nat Med 2007; 13:1504-1509.
41. Einav U, Tabach Y, Getz G, et al. Gene expression analysis reveals a strong signature of an interferon-induced pathway in childhood lymphoblastic leukemia as well as in breast and ovarian cancer. Oncogene 2005; 24:6367-6375.
42. Buess M, Nuyten DS, Hastie T, et al. Characterization of heterotypic interaction effects in vitro to deconvolute global gene expression profiles in cancer. Genome Biol 2007; 8:R191.
43. Weichselbaum RR, Ishwaran H, Yoon T, et al. An interferon-related gene signature for DNA damage resistance is apredictive marker for chemotherapy and radiation for breast cancer. Proc Natl Acad Sci USA 2008; 105:18490-18495.
44. Khodarev NN, Roach P, Pitroda SP, et al. STAT1 pathway mediates amplification of metastatic potential and resistance to therapy. PLoS One 2009; 4:e5821.
45. Gardner TA, Elzey BD, Hahn NM. Sipuleucel-T (Provenge) autologous vaccine approved for treatment of men with asymptomatic or minimally symptomatic castrate-resistant metastatic prostate cancer. Hum Vaccin Im-munother 2012; 8:534-539.